ABBV Stock - ABBVIE Q3 2025 Quarterly Results Explained - Earning Brief

Описание: AbbVie (ABBV) Q3 2025 financial performance in a nutshell:
AbbVie is quickly replacing Humira sales by buying new future therapies. Sales of new immunology drugs, Skyrizi and Rinvoq, are booming. Billions spent now secured long-term drug exclusivity until 2037.

Core drug sales grew strongly, but massive pipeline investment—totaling $2.68 billion in acquired R&D expenses—slashed the reported $0.10 diluted earnings per share by 88.6 percent, securing assets for long-term security beyond the Humira transition.

Immunology Revenue Growth, Strategic Pipeline Investment, Humira Biosimilar Transition, Biopharma Dividend Growth, Neuroscience Portfolio Expansion.

APPRECIATE YOUR SUPPORT ⭐ https://www.buymeacoffee.com/earningb... ⭐ THANK YOU!

---------------

📌 Disclaimer:
This channel is for entertainment and educational purposes only. I share my personal analysis and commentary — this is NOT financial advice. I'm NOT a financial advisor, accountant, or lawyer. All opinions are my own and may be wrong or outdated. Past performance doesn't guarantee future results. I'm NOT responsible for financial decisions made based on this content.

💡 Always do your own stock market research and consult a licensed advisor before investing.

🔗 Some links may be affiliate links, which support the channel at no extra cost to you. Feel free to search for products independently. Always research before buying.

Narration of the analysis is AI generated.